Objective: The endothelial glycocalyx has been shown to serve as a protective barrier between the fl owing blood and the vessel wall in experimental models. The aim of this study was to evaluate whether hypercholesterolemia is associated with glycocalyx perturbation in humans, and if so, whether statin treatment can restore this.
INTRODUCTION
Endothelial cells are shielded from direct exposure to the fl owing blood by a highly hydrated mesh of macromolecules, named the endothelial glycocalyx (1) . Its major components include proteoglycans with their associated glycosaminoglycans, such as hyaluronan and heparan sulphate, as well as glycoproteins bearing acidic oligosaccharides with terminal sialic acids. Recent intravital microscopic studies showed that the endothelial glycocalyx is 0.5 to 3 μm thick (2, 3) . Several decades ago, Gorog already found that sialic acid density in rabbits was decreased in predilection sites for atherosclerosis (4) . These fi ndings have now been corroborated, since loss of glycocalyx leads to a wide spectrum of vascular abnormalities in experimental models. These comprise increased vascular permeability as well as increased adhesion of leukocytes and thrombocytes to the vessel wall (5) (6) (7) (8) . Restoration of the glycocalyx is associated with reversal of these pro-atherogenic changes (5) . Collectively, there is growing evidence that the endothelial glycocalyx plays a central role in vascular homeostasis and could be of importance in protecting the vasculature against atherogenic insults.
Recently, our group developed a novel technique to estimate the volume of the endothelial glycocalyx in humans. Using this method, Nieuwdorp et al. showed that acute hyperglycemia results in a profound perturbation of the glycocalyx, coinciding with vascular dysfunction and activation of the coagulation system (9) . Glycocalyx loss was also shown to be present in patients with type 1 diabetes mellitus. Damage was most severe in patients with microalbuminuria (10, 11) . In experimental models, other risk factors such as oxygen radical stress, infl ammation and exposure to oxidized low-density lipoprotein (oxLDL) have also been shown to disrupt the glycocalyx (12) (13) (14) 8) .
In the present study we evaluated whether hypercholesterolemia is associated with glycocalyx perturbation in humans, and if so, whether statin treatment is able to reverse these derangements. For this purpose we selected patients with heterozygous familial hypercholesterolemia (FH), characterized by elevated LDL-cholesterol levels.
METHODS

Study population
We enrolled 13 non-smoking, male patients with heterozygous FH (DNA diagnosis and/or strong clinical suspicion based on lipid profi le, family history and/or presence of xanthomas, xanthelasmata or corneal arcus) without a history of cardiovascular disease or diabetes mellitus. Thirteen normocholesterolemic, non-smoking, healthy male subjects served as a control group. All subjects gave written informed consent, and approval was obtained from the internal review board of the Academic Medical Center. The study was carried out in accordance with the principles of the Declaration of Helsinki.
Study design
We measured systemic glycocalyx volume (V G ), safety and lipid profi les, and glycocalyx related parameters in FH patients after cessation of statin therapy for a minimum period of 4 weeks and 8 weeks after initiating intensive statin treatment (rosuvastatin 40 mg, QD). In view of the exploratory nature of the present experiment and the increased risk of cardiovascular disease in FH patients, a placebo-controlled trial was deemed unethical at this stage.
Normocholesterolemic subjects were used as controls. All experiments were performed after an overnight fast. Participants were asked to refrain from heavy physical exercise 24 h prior to the study visit. Blood pressure was measured three times, from which the mean of the last two measurements was used as systolic and diastolic blood pressure. All data and images were analyzed by lab staff and readers unaware of the clinical details and or stage of the protocol.
Estimation of endothelial glycocalyx volume
The endothelial glycocalyx allows limited access to plasma macromolecules and erythrocytes, whereas smaller tracers can permeate into the glycocalyx (15) . We estimated V G by subtracting circulating plasma volume from the intravascular distribution volume of a glycocalyx permeable tracer, i.e. neutral dextran 40, as previously published (9, 10, 16) . The intravascular distribution volume of labeled, autologous erythrocytes was used to quantify circulating blood volume (17) . In our hands, this method has an intersession coeffi cient of variation of 16 ± 12 % (18).
In summary, two cannulas were inserted in the antecubital veins of both forearms for the collection of blood and infusion of dextran 40 as well as labeled autologous erythrocytes. To quantify circulating plasma volume, 50 ml blood was drawn and centrifuged. Subsequently, 250 mg/ml of sodium fl uorescein was added to the erythrocyte fraction for 5 minutes. After washing, labeled erythrocytes were resuspended in saline to the initial volume and reinfused. Thickness of endothelial glycocalyx in individual capillary blood vessels was measured by orthogonal polarization spectral (OPS) imaging of the sublingual microcirculation (Cytometrics, Philadelphia, PA, USA) (18) . Briefl y, the width of fl owing erythrocytes was measured in 5 individual capillaries before and immediately after leukocyte passage. In healthy capillaries, the glycocalyx limits capillary blood fi lling by separating erythrocytes from the luminal endothelial surface. Since leukocytes transiently compress the capillary endothelial glycocalyx, the corresponding transient widening of the capillary erythrocyte column can be used to estimate capillary glycocalyx dimension (19) . Analysis of the images was performed with ImageJ (National Institutes of Health, USA) by a single observer, unaware of the clinical details of the participants. In our hands, this method has an intersession coeffi cient of variation of 15 ± 5 % (18).
Biochemical parameters
Total cholesterol, HDL-cholesterol, and triglycerides were measured by standard enzymatic methods (Roche Diagnostics, Basel, Switzerland). LDL-cholesterol was calculated using the Friedewald formula. OxLDL was measured using a commercially available ELISA (Mercodia, Uppsala, Sweden). Alanine aminotransferase and aspartate aminotransferase were measured by pyridoxalphosphate activation assay (Roche Diagnostics). Creatinin was measured by Jaff e´ kinetic colorimetric test (Roche Diagnostics) on Modular P800 (Roche Diagnostics). Glucose was assessed using the hexokinase method (Gluco-quant, Hitachi 917; Hitachi). HbA1C was measured by HPLC (Reagens Bio-Rad Laboratories, Veenendaal, the Netherlands) on a Variant II (Bio-Rad Laboratories). Plasma C-reactive protein (CRP) levels were measured with a commercially available assay (Roche, Switzerland). Hematocrit (Ht) was measured after centrifugation of heparinized blood at 10,000 rpm for 5 minutes (Hettich, Tuttlingen, Germany).
For further analysis, plasma aliquots were snap-frozen and stored at -80 °C. Quantitative total plasma hyaluronan levels were measured by ELISA (Echelon Biosciences, Salt Lake City, UT, USA) as was syndecan-1 (Diaclone, Besançon, France). Plasma hyaluronidase activity was determined with a previously described assay (20) .
Statistical analysis
Results are expressed as means ± SD. Diff erences between normocholesterolemic and hypercholesterolemic subjects were tested using an unpaired Student's t test (two-tailed). Diff erences within the hypercholesterolemic group with and without treatment were tested using a paired Student's t test (two-tailed). CRP and triglyceride levels are generally not normally distributed. Therefore, we present medians (interquartile range) and used non parametric tests for these values. The relation between V G as dependent variable and other parameters was explored using Pearson's or Spearman's correlation coeffi cient. Analyses were performed with SPSS version 11.5 (Chicago, IL, USA). A p value < 0.05 was considered statistically significant.
RESULTS
Clinical characteristics
Clinical characteristics of the participants are listed in Table 1 . As expected, FH patients who had discontinued statin treatment for a duration of 4 weeks, had substantially higher LDLcholesterol levels than the normocholesterolemic controls (LDL-cholesterol mean ± SD: 225 ± 57 mg/dL vs. 93 ± 24 mg/dL respectively). HDL-cholesterol levels, triglyceride levels, blood pressure as well as CRP were all within the normal range, but signifi cantly less favorable in FH patients compared to controls. Age, body mass index (BMI) as well as plasma glucose levels were comparable between groups.
Glycocalyx volume and hypercholesterolemia
Systemic glycocalyx volume (V G ) in untreated FH patients was substantially lower than in the normocholesterolemic control group (0.8 ± 0.3 L vs. 1.7 ± 0.6 L respectively, p < 0.001) (Figure 1 ). In normocholesteromic controls V G was correlated with plasma hyaluronan levels 
Glycocalyx volume after statin treatment
After 8 weeks treatment with rosuvastatin 40 mg QD LDL-cholesterol levels completely normalized to 95 ± 33 mg/dL (Table 1) . V G recovered partially (V G 1.1 ± 0.4 L, p = 0.04). Capillary endothelial glycocalyx thickness, determined using OPS imaging, followed a similar pattern.
Mean glycocalyx thickness was 0.4 ± 0.1 μm in patients without treatment and increased to 0.5 ± 0.1 μm after treatment (p = 0.17). Unfortunately, OPS images could only be analyzed in 8 out of 13 patients and 9 out of 13 controls due to technical diffi culties. After treatment, V G tended to be negatively correlated to leukocyte count (r = -0.523, p = 0.067). Besides that, the change in V G tended to be inversely correlated with the change in leukocyte count (ρ= -0.492, p = 0.087). There was no signifi cant correlation between (change in) V G and LDL-cholesterol.
In normocholesterolemic controls mean glycocalyx thickness was 0.5 ± 0.2 μm. 
Vascular permeability and glycocalyx-associated parameters
The 
DISCUSSION
In the present study we found a substantial reduction of V G in patients with FH compared to normocholesterolemic controls. After 8 weeks of intensive statin treatment, LDL-cholesterol levels completely normalized, yet V G only partially recovered. V G in FH patients was correlated with leukocyte count. Taking into account the cumulating evidence that glycocalyx perturbation enhances vulnerability of the vessel wall, our fi ndings imply that novel strategies aimed at restoring V G may be of interest to further optimize vascular resistance towards atherogenic insults. Increased vascular permeability has previously been described in FH patients (25) . Glycocalyx damage could contribute to this and thus to premature atherosclerosis which is often is seen in these patients.
FH is known to be associated with increased oxidant stress (21, 22) , illustrated by increased oxLDL levels in our patients, as well as increased infl ammatory mediators, such as CRP (26) .
Both oxLDL as well as infl ammatory mediators have been shown to have a detrimental impact on glycocalyx in experimental models (8, 23, 27) . In fact, increased oxygen radical stress has been suggested to be one of the principal mediators of glycocalyx perturbation. This is illustrated by the fi ndings that glycocalyx damage upon oxLDL exposure in hamsters could be prevented by radical scavengers (8) . Similarly, we previously found that glycocalyx damage by hyperglycemia in humans could be restored by infusion of the antioxidant N-acetylcysteine (10) . Unfortunately, statin therapy resulted in partly restoration of the endothelial glycocalyx only.
Although LDL and oxLDL levels normalized after rosuvastatin treatment, V G only partially recovered. A possible explanation is the short duration of treatment (8 wks) in light of the lifelong exposure to high cholesterol levels in FH patients. In contrast, many studies have shown rapid recovery of endothelial function upon statin treatment (28, 29) . Moreover, (change in) glycocalyx volume did not signifi cantly correlate with LDL-cholesterol levels, but tended to correlate with leukocyte count. This may imply a role of the infl ammatory activity, rather than LDL-cholesterol in glycocalyx perturbation. On the other hand, it has recently been suggested that endothelial 'memory' exists, as it was shown that vascular stress, mediated by oxidants, persisted following glucose normalization after a hyperglycemic period (30) . This may also be applicable to hypercholesterolemia-induced vascular stress. It could imply that hypercholesterolemia has longer lasting eff ects on the endothelium as well as the endothelial glycocalyx. Short-term lowering of cholesterol may not be suffi cient to overcome this endothelial 'memory' . Further studies are needed to evaluate whether long-term statin therapy is able to establish further restoration of the endothelial glycocalyx.
Obviously, statins have not been designed to restore the endothelial glycocalyx. Notably, we even observed an increase in hyaluronidase levels after rosuvastatin therapy. As hyaluronidase breaks down a major component of the glycocalyx, i.e. hyaluronan, increased levels could attenuate restoration despite the eff ective lowering of LDL-cholesterol. Whereas the exact cause of statin-associated increase in hyaluronidase is unclear, statins are known to upregulate KLF2, which in turn has been shown to increase hyaluronidase expression (31, 32) .
If restoration of the glycocalyx is to be reached, more direct targeting is likely to be achieved by modulating glycosaminoglycan metabolism, either by supporting glycosaminoglycan production or by preventing degradation. Such compounds showing larger eff ects on the endothelial glycocalyx may off er further protection towards atherogenic insults on top of statins.
Study limitations
This study has a relatively small sample size. Therefore, we chose to include a homogeneous group of healthy, non-smoking, male FH patients and normocholesterolemic control subjects with an overt diff erence in LDL-cholesterol. Whereas other baseline clinical characteristics also showed minor diff erences, these were all well within normal range. Secondly, the role of the endothelial glycocalyx as a target of damage and, thus, as a structure deserving protec- 
CONCLUSION
The endothelial glycocalyx is profoundly reduced in FH patients, which may contribute to increased atherogenic vulnerability. This perturbation is partially restored upon short-term statin therapy. Awaiting trials validating the protective role of an intact glycocalyx, the present fi ndings may suggest a need for novel interventions aimed at additional restoration of the glycocalyx.
